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Abstract Tau protein from Alzheimer disease (AD) brain is 
phosphorylated at eleven Ser/Thr-Pro and nine Serfrhr-X sites. 
The former sites are phosphorylated by proline-dependent protein 
kinases (PDPKs), the latter by non-PDPKs. The identities of 
both the PDPKs and non-PDPKs involved in AD tau hyper- 
phosphorylation are still to be established. In this study we have 
analyzed the interactions between a PDPK (GSK-3) and several 
non-PDPKs (A-kinase, C-kinase, CK-1, CaM kinase II) in the 
phosphorylation of one isoform (tau 39) of human tau. We found 
that the rate of phosphorylation of tan 39 by GSK-3 was in- 
creased several-fold if tau were first prephosphorylated by the 
non-PDPKs. Further, several Alzbeimer-like pitopes in tau can 
be induced only slowly after phosphorylation of tau by GSK-3 
alone. After a prephosphorylation of tau by the non-PDPKs, 
however, the rate of induction of these epitopes by GSK-3 is 
increased several-fold. These results suggest that one role of 
non-PDPK-catalyzed phosphorylation is the modulation of 
PDPK-catalyzed phosphorylation of tau in AD brain. 
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1. Introduction 
The paired helical filaments (PHFs) found in the brain of 
patients with Alzheimer disease (AD) are composed primarily 
of the microtubule-associated protein tau [1]. Compared to tau 
from normal brain, PHF-tau is in a hyperphosphorylated state 
[2]. The mechanism(s) leading to and the kinases responsible for 
the hyperphosphorylation of PHF-tau have not yet been iden- 
tified. 
One approach to identify the responsible kinases is to use 
purified tau as a substrate for known protein kinases in vitro. 
A comparison of the sites phosphorylated byindividual kinases 
with those known to be phosphorylated in PHF-tau should help 
in the identification of possible candidate kinases. Twenty 
phosphorylation sites have recently been identified in PHF-tau. 
Eleven of these sites are on Ser/Thr-Pro motifs and are there- 
fore phosphorylated by proline-dependent protein kinases 
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(PDPKs). The other nine sites are on Ser/Thr-X motifs and are 
probably phosphorylated by non-PDPKs [3]. Hence both 
PDPKs and non-PDPKs may participate in the hyper- 
phosphorylation of PHF-tau. 
The in vitro phosphorylation of tau by both PDPKs and 
non-PDPKs has been studied. The PDPKs include MAP kinase 
[4,5], cdk2 kinase [6], cdk2, cdk5 [7], and GSK-3 [8-10]. The 
non-PDPKs include cyclic AMP-dependent protein kinase (A- 
kinase) [11,12], protein kinase C [12-14], calcium/calmodulin- 
dependent protein kinase II (CaM kinase II) [12,15], calcium/ 
calmodulin kinase Gr [12], casein kinase 1 (CK-1) [12], and 
casein kinase-2 (CK-2) [12,16]. 
Several phosphorylation-dependent antibodies have been 
shown to react with PHF-tau. These include SMI31 (recognizes 
P-Ser-396, P-Ser-404) [17]), SMI34 (recognizes phosphorylated 
epitopes on either side of the microtubule-binding domains of 
tau) [17], PHF-1 (recognizes P-Ser-396) [18], and M4 (recog- 
nizes P-Thr-231) [19], among others. Antibodies that recognize 
dephosphorylation epitopes in tau include Tau-1 (recognizes 
dephosphorylated Set-199 and Ser-202 [20], 102C (recognizes 
dephosphorylated Ser-46) [21], and SM133 (recognizes 
dephosphorylated Ser-235 [17], among others. The above Alz- 
heimer-like pitopes can be induced after phosphorylation f
normal tau by various PDPKs in vitro [4,(~8,10]. Some of these 
epitopes are also induced after phosphorylation f tau by non- 
PDPKs [22]. 
In this study we have investigated how a PDPK may interact 
with non-PDPKs to produce the hyperphosphorylated state of 
PHF-tau. In this respect, we have analyzed how the specificity 
of GSK-3 (a PDPK) is affected when the initial phosphoryla- 
tion state of tau is altered by various non-PDPKs. We found 
that after such prephosporylation f tau by non-PDPKs (A- 
kinase, CK-1, CaM kinase II) the rate at which several Alz- 
heimer-like pitopes on tau can be induced by GSK-3 is greatly 
increased. 
2. Experimental 
2.1. Materials 
The human tau clone, tau 39 (kindly provided by M. Goedert), 
encodes for the tau isoform 3L that has three tandem C-terminal re- 
peats plus a 58-amino acid insert near the N-terminal end of the pol- 
ypeptide [23]. This tau was subcloned into the Ndel and EcoRI sites 
downstream of the T7 RNA polymerase promoter of the expression 
plasmid pRK172 [24]. The recombinant plasmid was transformed into 
E. coli BL 21 (DE3) cells [25] and screened by restriction enzymes. The 
cells were grown to an optical density of 0.6-1.0 at 600 nm. Expression 
was induced by adding 0.4 mM isopropyl thio-fl-D-galactoside, After 
shaking at 37°C for 5 h, the cells were collected by centrifugation and 
tau purified essentially as described in [26] with the following modifica- 
tions. The cells were lysed by ultrasonication in 80 mM Mes (pH 6.8) 
containing 5mM dithiothreitol. After centrifugation at120,000 x g tau 
was isolated from the extract by phosphocellulose chromatography 
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[27], heated in a boiling bath for 5 min followed by extraction i  2.5% 
perchloric acid [1]. 
CK-1, CK-2 [28] and GSK-3 [29] were purified from bovine brain. 
The GSK-3 preparation contained both the ~t and fl isoforms in the 
ratio 3:2. CaM kinase II [30] and C-kinase [31] were purified from rat 
brain. CaM kinase II was a gift from Brad McDonald, Burroughs- 
Welcome Laboratories; C-kinase was generously supplied by V. 
Chauhan of this Institute. The catalytic subunit of A-kinase, calmod- 
ulin and goat anti-mouse IgG conjugated toalkaline phosphatase w re 
purchased from Sigma Chemical Co. (St. Louis, MO, USA). The tau 
monoclonal ntibodies were obtained as follows: SMI31 and SMI34 
were purchased from Sternberger Monoclonal Inc. (Baltimore, MD, 
USA); PHF-1 (18) and M4 [19] were gifts from S. Greenberg, Burke 
Rehabilitation Center, Cornell Medical College (White Plains, NY, 
USA) and Y. Ihara, Institute for Brain Research, University of Tokyo 
(Tokyo, Japan), respectively; Tau-1 was a gift from L. Binder, Molec- 
ular Geriatrics Corp. (Lake Bluff, IL, USA). (y-32p]ATP was purchased 
from ICN Biomedicals (Costa Mesa, CA, USA). 
2.2. Methods 
Human tau 39 was phosphorylated byGSK-3 in a reaction mixture 
normally containing 0.15 mg/ml tau, 6 mM MgCI2, 10 mM 2-mercap- 
toethanol, 0.1 mM [~'-32P]ATP, 40 mM HEPES (pH 7.5), and GSK-3. 
Phosphorylation f tau by the other kinases was recently described by 
us [12]. Reactions were initiated at 30°C by addition of[y-~2P]ATP and, 
after the desired incubation time, aliquots removed and processed as 
described [32]. GSK-3 activity was measured using myelin basic protein 
as a substrate [33]. One unit of GSK-3 activity is defined as the amount 
of the kinase that will catalyze the incorporation f 1 nmo132P/min i to 
myelin basic protein (1 mg/ml) at 30°C. 
Immunoblotting of tau by the different tau antibodies was carried out 
as previously described [2]. The following dilutions of antibodies were 
used: SMI31 (1:75), SMI34 (1:75), PHF-1 (1:500), M4 (1: 1000), and 
Tau-1 (1 : 50,000). 
3. Results 
3.1. Phosphorylation of tau by different kinases 
We have examined the time course of phosphorylation of
human tau 39 (three tandem C-terminal repeats plus a 58- 
amino acid N-terminal insert) by a proline-dependent protein 
kinase (PDPK), GSK-3, and several non-PDPKs (A-kinase, 
C-kinase, CK-1, CK-2, CaM kinase II) (Fig. 1A). It can be seen 
that either CK-1 or CaM kinase II can rapidly catalyze the 
incorporation of above 1 mol 32p/mol tau in 15 min. Only a 
slight additional phosphorylation (<0.2 mol 32p) is promoted 
by CaM kinase II over the next 6 h. By contrast 32p incorpora- 
tion catalyzed by CK-1 is ~4.8 tool after 6 h and the reaction is 
still incomplete. 32p incorporation catalyzed by A-kinase, C- 
kinase and GSK-3 occur at slower rates, and reach 1.3, 1.6, and 
2.4 mol/mol tau, respectively, after 6 h incubation at 30°C. By 
contrast to the above five kinases human tau 39 was a very poor 
substrate for CK-2 (0.14 mol [32p/mol]tau after 6 h at 30°C) 
(results not shown). 
3.2. Phosphorylation of tau by GSK-3 after an initial 
phosphorylation by various non-PDPKs 
We have recently shown that prephosphorylation f bovine 
tau (a mixture of six isoforms) by A-kinase, C-kinase or CK-2 
stimulated a subsequent phosphorylation by GSK-3 [34]. We 
have therefore xamined the effect of prephosphorylation f 
human tau 39 on GSK-3-catalyzed phosphorylation. Tau 39 
was incubated in the absence of any kinase or in the presence 
of A-kinase, C-kinase, CK-1, and CaM kinase as shown in Fig. 
1A. After 2 h at 30°C, the reaction tubes were heated at 95°C 
for 5 rain to inactivate the kinases. [y-32p]ATP and GSK-3 were 
then added to the reaction tubes at 30°C and 32p incorporation 
into tau quantitated. The results are shown in Fig. lB. Pre- 
phosphorylation f tau by CK-1, C-kinase, CaM kinase II, and 
A-kinase stimulated 32p incorporation catalyzed by GSK-3. 
After 30 min incubation with GSK-3 the level of stimulation 
was 1.9-, 2.9-, 5.6-, and 8.2-fold, respectively, compared to tau 
that was not prephosphorylated (Fig. 1B). These results indi- 
cate that prephosphorylation f human tau 39 by non-PDPKs 
can stimulate the subsequent level of 32p incorporation 
achieved by GSK-3. 
3.3. Pattern of binding of tau antibodies to different species of 
phosphorylated tau 
Previous studies have shown that the epitopes to several tau 
antibodies are maximally induced only after prolonged (up to 
20 h) incubation with GSK-3 [8,10]. Since prephosphorylation 
of tau by non-PDPKs stimulate subsequent phosphorylation by
GSK-3 (Fig. 1B) we have surveyed whether the binding of 
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Fig. 1. Phosphorylation f human tau 39 by different kinases. (A) Comparison of tau phosphorylation byseveral kinases. Tau was phosphorylated 
by A-kinase ([]), C-kinase (o), CaM kinase II (A), GSK-3 (z~), and CK-1 (o). (B) Use of different prephosphorylated au species as substrates for 
GSK-3. Tau was incubated in the absence (z~) or presence of A-kinase ([]) C-kinase (o), CaM kinase II (A), or CK-1 (o) and unlabeled ATE After 
2 h at 30°C, the reactions were stopped by heating at 95°C for 5 min. After removing denatured kinases (spun at 10,000xg for 10 min), reaction 
mixtures were supplemented with [y-32P]ATP and GSK-3 and again incubated at 30°C. In both A and B, aliquots of the reaction mixtures were 
removed and processed as described [31]. 
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Fig. 2. Pattern of binding of tau antibodies to different species of 
phosphorylated tau. Non-phosphorylated tau (lane 1) or 
phosphorylated tau (lanes 2-12) were immunoblotted with Tau-1 (A), 
PHF-1 (B), SMI34 (C), SMI31 (D), and M4 (E). Tau was 
phosphorylated by GSK-3 (lane 2), A-kinase (lane 3), A-kinase + GSK- 
3 (lane 4), C-kinase (lane 5), C-kinase + GSK-3 (lane 6), CK-2 (lane 7), 
CK-2 + GSK-3 (lane 8), CK-1 (lane 9), CK-1 + GSK-3 (lane 10), CaM 
kinase II (lane 11), or CaM kinase II+GSK-3 (lane 12). Tau was 
phosphorylated for 2 h at 30°C when each kinase was used alone. When 
a combination ofkinases was used, phosphorylation was for 2 h by the 
first kinase followed by heating at 95°C for 5 min. The second kinase 
(GSK-3) was then added and phosphorylation continued at 30°C for 
1 h. In panel E, tau was not phosphorylated (lane 1) or phosphorylated 
by A-kinase+GSK-3 (lane 2), CK-1 +GSK-3 (lane 3), CaM kinase 
II + GSK-3 (lane 4), or GSK-3 (lane 5). 
different phosphorylation-dependent tau antibodies are also 
enhanced (or inhibited) under these conditions. For these stud- 
ies we prepared three categories of phosphorylated tau: (a) tau 
phosphorylated bythe five non-PDPKs; (b)tau phosphorylated 
by GSK-3; (c) tau phosphorylated by GSK-3 after an initial 
phosphorylation bythe non-PDPKs. The binding of several tau 
antibodies to these different phosphorylated tau species was 
then analyzed by immunoblotting (Fig. 2). Phosphorylation of
the epitope to Tau-1 is known to inhibit binding of this anti- 
body [8,10,20]. The binding of different phosphorylated tau 
species to Tau-1 is shown in Fig. 2, panel A. Compared to 
non-phosphorylated tau (lane 1), the binding of Tau-1 was 
significantly inhibited only after tau was first pre- 
phosphorylated by A-kinase (lane 4) or CaM kinase II (lane 
12). Phosphorylation by the other kinases, acting singly or in 
combination, did not significantly affect binding of Tau- 1 (Fig. 
2, panel A). The antibodies PHF-1 (panel B), SMI34 (panel C), 
SMI31 (panel D) and M4 (panel E) recognize only 
phosphorylated pitopes on tau [17-19]. None of these antibod- 
ies were found to bind to non-phosphorylated tau (Fig. 2, 
panels B-E, lane 1). PHF-1 (Fig. 2, panel B) recognized tau that 
was phosphorylated byGSK-3 alone (lane 2), or by a combina- 
tion of A-kinase + GSK-3 (lane 4), C-kinase + GSK-3 (lane 6), 
CK-1 + GSK-3 (lane 10), and CaM kinase II + GSK-3 (lane 12). 
SMI34 recognized mainly tau that was phosphorylated by the 
combined actions of CK-1 and GSK-3 (Fig. 2, panel C, lane 10). 
With SMI31 (Fig. 2, panel D) the highest level of binding was 
achieved when tau was phosphorylated by a combination of 
CK- I+GSK-3 (lane 10). Binding of the antibody M4 
(Fig. 2, panel E) was promoted when tau was phosphorylated 
by GSK-3 alone (lane 5) or a combination of CK-1 +GSK-3 
(lane 3) and CaM kinase II +GSK-3 (lane 4). These results 
suggest that the epitopes of various tau antibodies become good 
substrates for GSK-3 after tau is first prephosphorylated by a 
non-PDPK. 
3.4. Rapid reduction of  epitopes by a combination of  kinases 
From the results of Fig. 2, the epitopes of various tau anti- 
bodies become better substrates for GSK-3 when tau is first 
prephosphorylated by A-kinase, CK-1 or CaM kinase II but 
not by C-kinase or CK-2. We have further explored this inter- 
action between GSK-3 and non-PDPKs by analyzing the time 
course of inhibition (Tau-1) or enhancement (PHF-1, SMI31, 
SMI34, M4) of the binding of tau antibodies to different species 
of phosphorylated tau. Fig. 3 shows the results achieved with 
Tau-1. A significant decrease in Tau-1 binding occurs only after 
21 h of phosphorylation f tau either by GSK-3 alone (Fig. 3, 
panel A) or a combination of CK-1 + GSK°3 (Fig. 3, panel C). 
A decrease in Tau-1 binding is observed after only 1 h phospho- 
rylation of tau by a combination of either A-kinase + GSK-3 
(Fig. 3, panel B) or CaM kinase II + GSK-3 (Fig. 3, panel D). 
However, whereas A-kinase+GSK-3-catalyzed phosphoryla- 
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Fig. 3. Time course of inhibition of Tau-1 binding by different combi- 
nation of kinases. Tau was not prephosphorylated (A) or was pre- 
phosphorylated for2 h by A-kinase (B), CK-1 (C), and CaM kinase II 
(D). All samples were then heated at 95°C for 5 rain, transferred back 
to 30°C and GSK-3 added to all tubes. Aliquots of the reaction mix- 
tures were then removed at 0 min (lane 1), 5 rain (lane 2), 15 min (lane 
3), 30 min (lane 4), 1 h (lane 5), 3 h (lane 6), 6 h (lane 7), and 21 h (lane 
8). All samples were then immunoblotted with Tau-1. From the results 
of Fig. 2 prephosphorylation of tau either by C-kinase or CK-2 did not 
significantly promote inhibition of Tau- 1 binding or increase of PHF- 1, 
SMI31, SMI34, M4 binding (below) and were therefore not tested 
further. 
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Fig. 4. Time course of induction of SMI31 and PHF-1 binding by different combination ofkinases. Tau that was not prephosphorylated (A,E) or 
was prephosphorylated by A-kinase (B,F), CK- 1 (C,G), and CaM kinase II (D,H) was then further phosphorylated by GSK-3. Aliquots of the reaction 
mixtures were removed at different times and immunoblotted ither with SMI31 (A-D) or PHF-1 (E-H). Lane numbers and phosphorylation times 
are the same as in Fig. 3. 
tion completely abolished Tau-1 binding after only 3 h (Fig. 3, 
panel B), such binding only slowly disappeared after phospho- 
rylation of tau by CaM kinase II + GSK-3 and is still apparent 
after 21 h (Fig. 3, panel D). 
Fig. 4 shows the time course of induction of the SMI31 
(panels A-D) and PHF-1 (panels E-H) epitopes. Phosphoryla- 
tion of tau with GSK-3 alone requires greater than 6 h phos- 
phorylation to achieve maximal binding of either antibody 
(panels A and E). However, both of these epitopes are rapidly 
induced by GSK-3 if tau is first prephosphorylated by A-kinase 
(panels B and F) or CaM kinase II (panels D and H). Pre- 
phosphorylation f tau by CK-1 rapidly induced the SMI31 
epitope (panel C) but only slightly improved binding of PHF-1 
compared to that promoted by GSK-3 alone (compare panels 
95 
68 
M4 
0' 5' 15' 30' 1 h 3 h 6 h21 h 
GSK-3 
SMI 34 
0' 5' 15' 30' 1 h 3 h 6 h21 h 
95- -  
A. 68- -  D. 
GSK-3 
95 
68 
95 
68 
CK-1 + GSK-3 
B. 68 E. 
CK-1 + GSK-3 
12345 678 
C. 
CAM kin II + GSK-3 
123456 78  
Fig. 5. Time course of induction of M4 and SMI34 binding by different combination ofkinases. Tau that was not prephosphorylated (A,D) or was 
prephosphorylated by CK-1 (B,E), and CaM kinase II (C) was then further phosphorylated by GSK-3. Aliquots of the reaction mixtures were removed 
at different times and immunoblotted wither with M4 (A-C) or SMI34 (D,E). Lane numbers and phosphorylation times are the same as in Fig. 3. 
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E and G). Among the three non-PDPKs (A-kinase, CK-1, CaM 
kinase II), prephosphorylation of tau by CK-1 and CaM kinase 
II are best for rapid induction of the SMI31 and PHF-1 epi- 
topes, respectively, by GSK-3. Both epitopes are maximally 
induced in about 1 h under these circumstances compared to 
21 h needed for their maximal induction by GSK-3 alone (Fig. 
4, compare panels A,C, and E,H, respectively). In only 5 rain 
prephosphorylation f tau by CK-1 (and to a lesser degree, 
A-kinase and CaM kinase II also) induce binding of SMI31 
several-fold. Under these conditions, GSK-3 alone only mini- 
mally induce this epitope (compare lane 2 in panels A and C). 
A similar conclusion is also true for induction of the PHF-I 
epitope when tau is prephosphorylated by CaM kinase II (com- 
pare lane 2 in panels E and H, Fig. 4). 
Fig. 5 shows the time course of induction of the M4 (A-C) 
and SMI34 (D-E) epitopes. Both of these epitopes are maxi- 
mally induced only after 21 h phosphorylation with GSK-3 
alone (Fig. 5, panels A and D). As shown previously (Fig. 2, 
panel C) recognition of the SMI34 epitope by GSK-3 is pro- 
moted when tau is first prephosphorylated mainly by CK-1. 
With GSK-3 alone significant binding of SMI34 required about 
6 h incubation (Fig. 5, panel D). After prephosphorylation by 
CK-1, significant binding of this antibody was detected after 
only 5 min incubation, but required ~6 h to reach a maximum. 
Prephosphorylation f tau with either CK-1 (panel B) or CaM 
kinase II (panel C) increased the rate and extent of binding of 
M4 to tau. For this purpose CaM kinase II is better. Binding 
of M4 is increased several-fold over control after only 5 min 
phosphorylation with CaM kinases II + GSK-3. Maximal bind- 
ing is reached in - 1 h compared to ~21 h when GSK-3 alone is 
used (Fig. 5, compare panels A and C). The results outlined in 
Figs. 3-5 indicate that after tau is first prephosphorylated by 
a non-PDPK (A-kinase, CK-1, CaM kinase II, depending on 
epitope being tested) the epitopes of several antibodies can be 
rapidly induced (SMI31, SMI34, PHF1, M4) or inhibited (Tau- 
1) by GSK-3 compared to tau that is not prephosphorylated. 
4. Discussion 
In the present study we have analyzed the phosphorylation 
of one isoform of human tau - tau 39. This isoform has three 
(of four) tandem C-terminal repeats and a 58-amino acid insert 
near the N-terminal end of the molecule [23]. CK-1 and CaM 
kinase II can rapidly phosphorylate his tau isoform, whereas 
phosphorylation catalyzed by A-kinase, C-kinase, CK-2, and 
GSK-3 proceed at a slower ate. A prior phosphorylation f tau 
by CK-1, C-kinase, CaM kinase II, and A-kinase was found to 
stimulate a subsequent phosphorylation catalyzed by GSK-3. 
C-kinase [34], A-kinase, CK-1, and CK-2 [35], have all been 
previously shown to modulate GSK-3 activity by pre- 
phosphorylation of protein substrates. This is the first report, 
however, of such modulation by CaM kinase II. 
Another major finding of this study is that prephosphoryla- 
tion of tau 39 by non-PDPKs permits a subsequent phosphoryl- 
ation by GSK-3 to rapidly phosphorylate some of the same 
epitopes een in PHF-tau. Previous studies (reproduced here 
with GSK-3) have shown that prolonged incubation (16-20 h) 
oftau with MAP kinase [4,5], GSK-3 [8,10], cdk2, and cdk5 [7] 
are required to maximally induce the binding of several of the 
phosphorylation-dependent tau antibodies used here. Phos- 
phorylation of protein in cells is a relatively rapid event (sec- 
onds to minutes). Hence, the prolonged time of incubation 
required to induce maximal binding of the different au anti- 
bodies suggests that the epitopes to these antibodies are poor 
substrates for GSK-3, MAP kinase, cdk2 and cdk5. The results 
presented in this study suggest that the epitopes to the various 
tau antibodies become very good substrates for GSK-3 (and 
maybe other PDPKs) after an initial phosphorylation f tau by 
a non-PDPK. Under these conditions, significant enhancement 
of binding of several of the antibodies occur relatively rapidly. 
For instance, after prephosphorylation f tau by CaM kinase 
II, GSK-3 can increase the binding of PHF-1 and M4 antibod- 
ies several-fold in only 5 rain. Without such prephosphorylation 
significant binding of these antibodies is only observed after 
30-60 rain incubation with GSK-3. Similarly, the time required 
for maximal binding of these antibodies is decreased from 
~21 h (no prephosphorylation) to ~1 h (with prephosphor- 
ylation). 
Our results also indicate that prephosphorylation f tau by 
a non-PDPK can differentially affect he induction of the differ- 
ent tau antibody epitopes. For instance, prephosphorylation of 
tau by CaM kinase II is best for rapidly inducing the PHF-1 
and M4 epitopes but not the SMI31 or SMI34 epitopes (CK-1 
is best in both cases). Similarly, prephosphorylation of tau by 
A-kinase promote an increased subsequent rate of induction of 
the SMI31 and PHF-1 epitopes by GSK-3. Such pre- 
phosphorylation, however, did not promote induction of either 
the SMI34 or M4 epitopes. In addition, even though pre- 
phosphorylation of tau by C-kinase increased subsequent 32p 
incorporation by GSK-3, it only minimally affected the rate of 
induction of several epitopes by GSK-3. These findings suggest 
that after phosphorylation by a non-PDPK such as A-kinase, 
tau may undergo a conformational change. Such conforma- 
tional change may promote binding of some antibodies (such 
as PHF-I), may inhibit binding of others (such as Tau-1), 
whereas the binding of still others (such as SMI34) may remain 
unaffected. 
The results of this study suggest a possible dual role for the 
participation of non-PDPKs in the hyperphosphorylation of 
PHF-tau. Such hyperphosphorylation hasbeen shown to occur 
almost equally at Ser/Thr-Pro and Ser/Thr-X sites [3]. Hence, 
the first possible role of non-PDPKs (their numbers and identi- 
ties are still obscure) will be to phosphorylate he Ser/Thr-X 
sites found in PHF-tau. The second possible role of non- 
PDPKs is a direct consequence of the first. After tau is 
phosphorylated by non-PDPKs its conformation would be so 
changed as to modulate the specificities of subsequent phos- 
phorylation by PDPKs (in a similar way as shown in this study). 
Modulation of tau hyperphosphorylation by PDPK-PDPK in- 
teractions are also possible. Prior phosphorylation of tau by 
TPK II/cdk5 (a PDPK) has been reported to increase the extent 
of a subsequent phosphorylation catalyzed by TPKI/GSK-3 
(another PDPK) [36]. Unlike our study, however, prolonged 
incubation of the prephosphorylated tau with GSK-3 was still 
required to observe such increased level of phosphorylation 
[36]. It is not known whether prephosphorylation f tau by 
TPK II/cdk5 can increase the rate at which Alzheimer-like 
epitopes in tau are induced by GSK-3 in a way similar to that 
observed with non-PDPKs in this study. 
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